Clinical Trials Logo

Clinical Trial Summary

The purpose of this study is to develop a database containing clinical and laboratory information for patients with Leigh syndrome. The goal is to provide a greater understanding of Leigh syndrome allowing further characterization of this disease.


Clinical Trial Description

Leigh syndrome, also known as juvenile sub-acute necrotizing encephalopathy, is a progressive neurodegenerative disorder associated with dysfunction of mitochondrial oxidative phosphorylation (OXPHOS). First described in 1951 by British neuropsychiatrist Archibald Denis Leigh, the condition has evolved from a post mortem diagnosis to a clinical entity with characteristic radiologic and laboratory findings. Leigh syndrome is a rare and heterogeneous disease, finding a substantial number of patients to study is difficult. The lack of natural history data in Leigh syndrome and the small number of patients included in clinical reports thus far has limited the ability to fully comprehend the progression of this disease and assess prognostic factors. A Leigh syndrome database will help improve our understanding of this rare disease leading to an improved ability to predict outcomes and/or improve treatment paradigms. Collecting natural history data on Leigh syndrome and integrating this information into a database will be useful in understanding the course of the disease and identifying trends. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03137355
Study type Observational [Patient Registry]
Source The University of Texas Health Science Center, Houston
Contact Mary Kay Koenig, MD
Phone 713-500-7164
Email leigh@uth.tmc.edu
Status Recruiting
Phase
Start date June 17, 2015
Completion date June 17, 2030

See also
  Status Clinical Trial Phase
Completed NCT04378075 - A Study to Evaluate Efficacy and Safety of Vatiquinone for Treating Mitochondrial Disease in Participants With Refractory Epilepsy Phase 2/Phase 3
Completed NCT01721733 - Safety and Efficacy Study of EPI-743 in Children With Leigh Syndrome Phase 2
Withdrawn NCT05277363 - A Study of the Natural Course of SURF1 Deficiency
Completed NCT02544217 - A Dose-escalating Clinical Trial With KH176 Phase 1
Recruiting NCT01793168 - Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Completed NCT02352896 - Long-Term Safety and Efficacy Evaluation of EPI-743 in Children With Leigh Syndrome Phase 2
Recruiting NCT05554835 - Global Registry and Natural History Study for Mitochondrial Disorders
Withdrawn NCT03747328 - ABI-009 (Nab-sirolimus) in Patients With Genetically-confirmed Leigh or Leigh-like Syndrome Phase 2